A Review on the Role of the Different Types of Immunotoxins in the Treatment of Prostate Cancer

Document Type : Review Article

Authors

1 Department of Medical Biotechnology, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran

2 Assistant Professor, Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran

3 Professor, Department of Medical Biotechnology, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran

Abstract

Prostate cancer is the second most frequent cancer and the fifth leading cause of cancer death in men. Many patients with metastatic prostate cancer die due to lack of effective treatment. Therefore, new therapeutic strategies are needed. Due to the local expression of prostate cancer antigens, evaluation of their existence in cancerous tissues would probably result in introducing new biomarkers for diagnosis and prognosis, as well as treatment of prostate cancer. Hence, specific immunotherapy against the new biomarkers may be a new way to treat and improve the management of prostate cancer. Immunotoxin therapies are novel targeted cancer therapies in which a toxin is a fusion of a monoclonal antibody. Immunotoxins selectively operate against the target cell due to the specific antibody, and kill cells through bacterial or plant toxin. So, immunotoxin is a promising candidate for therapeutic applications in patients with prostate cancer. Considering the importance of immunotoxins in the treatment of patients with prostate cancer, the purpose of this study was to review various immunotoxins used in prostate cancer in previous preclinical studies and finally, we made suggestions for the advancement of future studies.

Keywords

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
  2. Keyes M, Crook J, Morton G, Vigneault E, Usmani N, Morris WJ. Treatment options for localized prostate cancer. Can Fam Physician 2013; 59(12): 1269-74.
  3. Incrocci L. Radiotherapy for prostate cancer and sexual health. Transl Androl Urol 2015; 4(2): 124-30.
  4. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373(8):737-46.
  5. Chen L, Qiu X, Wang R, Xie X. The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: A systematic review. Sci Rep 2014; 4: 4818.
  6. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65(2): 467-79.
  7. Coulson A, Levy A, Gossell-Williams M. Monoclonal antibodies in cancer therapy: mechanisms, successes and limitations. West Indian Med J 2014; 63(6): 650-4.
  8. Singh S, Kumar NK, Dwiwedi P, Charan J, Kaur R, Sidhu P, et al. Monoclonal antibodies: A review. Curr Clin Pharmacol 2018; 13(2): 85-99.
  9. Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: The role of the linkage between components. Toxins (Basel) 2011; 3(7): 848-83.
  10. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006; 6(7): 559-65.
  11. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23(9): 1126-36.
  12. Kreitman RJ. Immunotoxins for targeted cancer therapy. In: Lorberboum-Galski H, Lazarovici P. Chimeric Toxins. 1st ed. ‎Boca Raton, FL: CRC Press; 2002. p. 219-37.
  13. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007; 58: 221-37.
  14. Di PC, Willuda J, Kubetzko S, Lauffer I, Tschudi D, Waibel R, et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 2003; 9(7): 2837-48.
  15. Fitzgerald DJ, Kreitman R, Wilson W, Squires D, Pastan I. Recombinant immunotoxins for treating cancer. Int J Med Microbiol 2004; 293(7-8): 577-82.
  16. Phillips JM, Catarinicchia S, Krughoff K, Barqawi AB. Cryotherapy in prostate cancer. J Clin Urol 2014; 7(5): 308-17.
  17. Mathew M, Verma RS. Humanized immunotoxins: A new generation of immunotoxins for targeted cancer therapy. Cancer Sci 2009; 100(8): 1359-65.
  18. Antignani A, Fitzgerald D. Immunotoxins: The role of the toxin. Toxins (Basel) 2013; 5(8): 1486-502.
  19. Zahaf NI, Schmidt G. Bacterial toxins for cancer therapy. Toxins (Basel) 2017; 9(8): 236.
  20. Polito L, Djemil A, Bortolotti M. Plant toxin-based immunotoxins for cancer therapy: A short overview. Biomedicines 2016; 4(2): E12.
  21. Alewine C, Hassan R, Pastan I. Advances in anticancer immunotoxin therapy. Oncologist 2015; 20(2): 176-85.
  22. Allured VS, Collier RJ, Carroll SF, McKay DB. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci USA 1986; 83(5): 1320-4.
  23. Ogata M, Chaudhary VK, Pastan I, Fitzgerald DJ. Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J Biol Chem 1990; 265(33): 20678-85.
  24. Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, Fitzgerald DJ, et al. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 2009; 113(16): 3792-800.
  25. Murphy JR. Mechanism of diphtheria toxin catalytic domain delivery to the eukaryotic cell cytosol and the cellular factors that directly participate in the process. Toxins (Basel) 2011; 3(3): 294-308.
  26. Gadadhar S, Karande AA. Abrin immunotoxin: targeted cytotoxicity and intracellular trafficking pathway. PLoS One 2013; 8(3): e58304.
  27. Choudhary S, Mathew M, Verma RS. Therapeutic potential of anticancer immunotoxins. Drug Discov Today 2011; 16(11-12): 495-503.
  28. Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, et al. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Clin Cancer Res 2013; 19(1): 148-57.
  29. Ahmadzadeh V, Farajnia S, Hosseinpour Feizi MA, Khavarinejad RA. Design, expression and characterization of a single chain anti-CD20 antibody; a germline humanized antibody derived from Rituximab. Protein Expr Purif 2014; 102: 45-51.
  30. Veisi K, Farajnia S, Zarghami N, Khorshid HR, Samadi N, Safdari Y, et al. Development and evaluation of a Cetuximab-based humanized single chain antibody against EGFR-overexpressing tumors. Drug Res (Stuttg) 2015; 65(12): 624-8.
  31. Adams GP, McCartney JE, Tai MS, Oppermann H, Huston JS, Stafford WF 3rd, et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 1993; 53(17): 4026-34.
  32. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2(10): 750-63.
  33. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012; 30(15): 1822-8.
  34. Wayne AS, Bhojwani D, Silverman LB, Richards K, Stetler-Stevenson M, Shah NN, et al. A novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase i study in pediatric acute lymphoblastic leukemia (ALL). Blood 2011; 118(21): 248.
  35. Schweizer MT, Drake CG. Immunotherapy for prostate cancer: Recent developments and future challenges. Cancer Metastasis Rev 2014; 33(2-3): 641-55.
  36. Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST. Prostate-specific membrane antigen-based therapeutics. Adv Urol 2012; 2012: 973820.
  37. Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M. New strategies in prostate cancer: Prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. Clin Cancer Res 2016; 22(1): 9-15.
  38. Fracasso G, Bellisola G, Cingarlini S, Castelletti D, Prayer-Galetti T, Pagano F, et al. Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate 2002; 53(1): 9-23.
  39. Wolf P, Gierschner D, Buhler P, Wetterauer U, Elsasser-Beile U. A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells. Cancer Immunol Immunother 2006; 55(11): 1367-73.
  40. Wolf P, Alt K, Wetterauer D, Buhler P, Gierschner D, Katzenwadel A, et al. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer. J Immunother 2010; 33(3): 262-71.
  41. Zhang F, Shan L, Liu Y, Neville D, Woo JH, Chen Y, et al. An anti-PSMA bivalent immunotoxin exhibits specificity and efficacy for prostate cancer imaging and therapy. Adv Healthc Mater 2013; 2(5): 736-44.
  42. Michalska M, Schultze-Seemann S, Bogatyreva L, Hauschke D, Wetterauer U, Wolf P. In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer. Oncotarget 2016; 7(16): 22531-42.
  43. Noll T, Schultze-Seemann S, Kuckuck I, Michalska M, Wolf P. Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737. Cancer Immunol Immunother 2018; 67(3): 413-22.
  44. Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, et al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 2006; 12(8): 2591-6.
  45. Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L, et al. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci USA 2012; 109(29): 11782-7.
  46. Shan L, Liu Y, Wang P. Recombinant Immunotoxin Therapy of solid tumors: Challenges and strategies. J Basic Clin Med 2013; 2(2): 1-6.
  47. Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH. Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity. Prostate 2010; 70(12): 1286-94.
  48. Michalska M, Schultze-Seemann S, Kuckuck I, Wolf P. In vitro evaluation of humanized/de-immunized anti-PSMA immunotoxins for the treatment of prostate cancer. Anticancer Res 2018; 38(1): 61-9.
  49. Taeb J, Asgari M, Abolhasani M, Farajollahi MM, Madjd Z. Expression of prostate stem cell antigen (PSCA) in prostate cancer: a tissue microarray study of Iranian patients. Pathol Res Pract 2014; 210(1): 18-23.
  50. Kessler C, Pardo A, Tur MK, Gattenlohner S, Fischer R, Kolberg K, et al. Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer. J Cancer Res Clin Oncol 2017; 143(10): 2025-38.
  51. Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002; 62(9): 2546-53.
  52. Mohsenzadegan M, Saebi F, Yazdani M, Abolhasani M, Saemi N, Jahanbani F, et al. Autoantibody against new gene expressed in prostate protein is traceable in prostate cancer patients. Biomark Med 2018; 12(10): 1125-38.
  53. Mohsenzadegan M, Shekarabi M, Madjd Z, Asgari M, Abolhasani M, Tajik N, et al. Study of NGEP expression pattern in cancerous tissues provides novel insights into prognostic marker in prostate cancer. Biomark Med 2015; 9(4): 391-401.
  54. Mohsenzadegan M, Tajik N, Madjd Z, Shekarabi M, Farajollahi MM. Study of NGEP expression in androgen sensitive prostate cancer cells: A potential target for immunotherapy. Med J Islam Repub Iran 2015; 29: 159.
  55. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol 2014; 15(11): e493-e503.
  56. Kalantari E, Abolhasani M, Roudi R, Farajollahi MM, Farhad S, Madjd Z, et al. Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer. Int J Exp Pathol 2019; 100(2): 123-32.
Journal of Isfahan Medical School
Volume 37, Issue 530 - Serial Number 530
March and April 2019
Pages 655-666

Files

History

  • Receive Date: 19 June 2019
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics